Rare cases of mesothelioma have been described with mutations in KRAS, NRAS [27] and potential oncogenic fusions involving ALK and EWSR1 rearrangements [31–33], as well as inactivating mutations in VHL raising the possibility of targeted therapy in such cases [34]. This evidence concerns the gene ALK and mesothelioma.